Evidence-Based Medicine Guidelines
Aromatase inhibitors vs. tamoxifen in postmenopausal women with early breast cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Aromatase Inhibitors Vs. Tamoxifen in Postmenopausal Women With Early Breast Cancer." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/454308/all/Aromatase_inhibitors_vs__tamoxifen_in_postmenopausal_women_with_early_breast_cancer.
Aromatase inhibitors vs. tamoxifen in postmenopausal women with early breast cancer. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. https://evidence.unboundmedicine.com/evidence/view/EBMG/454308/all/Aromatase_inhibitors_vs__tamoxifen_in_postmenopausal_women_with_early_breast_cancer. Accessed January 18, 2025.
Aromatase inhibitors vs. tamoxifen in postmenopausal women with early breast cancer. (2024). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/454308/all/Aromatase_inhibitors_vs__tamoxifen_in_postmenopausal_women_with_early_breast_cancer
Aromatase Inhibitors Vs. Tamoxifen in Postmenopausal Women With Early Breast Cancer [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. [cited 2025 January 18]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/454308/all/Aromatase_inhibitors_vs__tamoxifen_in_postmenopausal_women_with_early_breast_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Aromatase inhibitors vs. tamoxifen in postmenopausal women with early breast cancer
ID - 454308
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/454308/all/Aromatase_inhibitors_vs__tamoxifen_in_postmenopausal_women_with_early_breast_cancer
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
